NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
Clinical Trials
26 trialsNCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT01821612 2025-01-13
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase EARLY_PHASE1 Completed
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT06326736 2024-03-22
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Jinling Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT03373188 2024-03-20
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Emory University
Phase 1 Completed
NCT05083247 2023-05-23
STEREOPAC
Erasme University Hospital
Phase 2 Recruiting
NCT03199144 2022-06-23
CKPancreas
Centre Francois Baclesse, Luxembourg
Phase 2 Withdrawn
NCT01591733 2021-05-28
FOLFIRINOX + RT for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT03718650 2021-02-08
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Withdrawn
NCT03891472 2019-11-13
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
Medical University of Silesia
Phase 2 Completed
NCT02301143 2019-03-20
LAPACT
Celgene
Phase 2 Completed
NCT01900327 2018-05-11
NEOPA
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT00463840 2017-12-05
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
NYU Langone Health
Phase 1/2 Terminated
NCT00766636 2016-05-19
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01754623 2015-08-13
GTX-RT in Borderline Resectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01419002 2015-07-29
Net-Pac
CHIR-Net
Phase 3 Terminated
NCT00253526 2015-04-28
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01521702 2015-03-20
NEOPAC
Institut Paoli-Calmettes
Phase 3 Completed
NCT00482625 2014-10-16
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003769 2014-09-10
Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer
Indiana University
Phase 2 Completed
NCT01760694 2014-08-15
Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer
Southwestern Regional Medical Center
Phase NA Terminated
NCT00487851 2013-04-12
Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer
Karolinska Institutet
Phase 2 Withdrawn
NCT00500968 2011-04-07
Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail
Karolinska Institutet
Phase NA Completed
NCT00003332 2011-03-28
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
NYU Langone Health
Phase 1/2 Completed